Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2025)

Xeris Biopharma Holdings' Interest Expenses history spans 6 years, with the latest figure at $7.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 7.11% year-over-year to $7.2 million, compared with a TTM value of $29.1 million through Dec 2025, down 4.61%, and an annual FY2025 reading of $29.1 million, down 4.59% over the prior year.
  • Interest Expenses for Q4 2025 was $7.2 million at Xeris Biopharma Holdings, down from $7.3 million in the prior quarter.
  • The five-year high for Interest Expenses was $8.0 million in Q2 2024, with the low at $1.8 million in Q2 2021.
  • Average Interest Expenses over 5 years is $5.4 million, with a median of $6.7 million recorded in 2023.
  • Year-over-year, Interest Expenses plummeted 61.22% in 2021 and then soared 143.15% in 2022.
  • Tracing XERS's Interest Expenses over 5 years: stood at $1.8 million in 2021, then soared by 143.15% to $4.4 million in 2022, then surged by 60.5% to $7.0 million in 2023, then rose by 10.12% to $7.7 million in 2024, then dropped by 7.11% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Interest Expenses are $7.2 million (Q4 2025), $7.3 million (Q3 2025), and $7.4 million (Q2 2025).